Ajanta Pharma gets USFDA approval for Entacapone Tablet
DSIJ Intelligence / 04 Sep 2017
Pharmaceutical major Ajanta Pharma Limited has received final approval from the USFDA for Entacapone Tablet, which is a bioequivalent generic version of Comtan 1 Tablet.
Pharmaceutical major Ajanta Pharma Limited has received final approval from the USFDA for Entacapone Tablet, which is a bioequivalent generic version of Comtan 1 Tablet. The company will be launching the product shortly in 200 mg strength tablets. The drug is part of the growing portfolio of products that Ajanta Pharma has developed for the US market. In total, Ajanta has 35 Abbreviated New Drug Applications (ANDAs) of which it has final approvals for 20 ANDAs, tentative approvals for two ANDAs while and 13 ANDAs are under review with the USFDA.
Meanwhile, the stock was trading up by 0.05% at Rs 1,201 per share on the BSE at 0926 hours. It opened at Rs 1,211.10 per share and touched its intraday high and low at Rs 1,215.65 and Rs 1,201.55 per share, respectively. The stock attracted a total traded volume of 34,497 shares and traded value of Rs 417.58 lakhs on the NSE at 0931 hours. Its 52-week high stood at Rs 2,125 as on October 4, 2016 and its 52-week low was at Rs 1,135 as on August 22, 2017.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.